EPITOPE Study
PI: Deborah Albright, MD
A Double-Blind, Placebo-Controlled, Randomized Phase III Trial to Assess the Safety and Efficacy Of Viaskin® Peanut in Peanut-Allergic Young Children 1-3 Years of Age (EPITOPE study)
Clinical Phase 3 trial assessing the safety and efficacy of Viaskin® Peanut in toddlers. Subjects blindly randomized 2 to 1 to either a peanut 250 mcg patch or placebo patch for 12 months with the option to continue to open label study after the first year. Food challenges are required, and subjects must enroll before their fourth birthday.
EPOPEX Study
PI: Deborah Albright, MD
Epitope Open-Label Extension Study to Evaluate the Long-Term Clinical Benefit and Safety Of Dbv712 In Peanut-Allergic Children (Epopex)
Open label 36-month study for subjects who completed the Epitope Study. To assess the clinical benefit of Viaskin® Peanut after up to 3 years of epicutaneous immunotherapy (EPIT) to induce/maintain desensitization to peanut in peanut-allergic children and evaluate the safety of long-term treatment with Viaskin® Peanut in peanut-allergic children.
AZ Tate Study
PI: Allyson Larkin, MD
An open-label study to evaluate the pharmacokinetics and pharmacodynamics and long-term safety of Benralizumab administered Subcutaneously in Children with Severe Eosinophilic Asthma.
This open label study will evaluate the long-term safety of Benralizumab and the pharmacodynamics of the drug in the body of children aged 6 to 11 years with severe eosinophilic asthma. This study consists of multiple research visits and administration of Benralizumab, which is currently approved for ages 12 and up.